Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot, Exploratory Clinical Trial to Evaluate the Safety of Using Continuous IV Infusion of Tirofiban (24 Hours) Including Its Efficacy in Improving Perfusion Post Mechanical Thrombectomy in Acute Ischemic Stroke

Trial Profile

A Pilot, Exploratory Clinical Trial to Evaluate the Safety of Using Continuous IV Infusion of Tirofiban (24 Hours) Including Its Efficacy in Improving Perfusion Post Mechanical Thrombectomy in Acute Ischemic Stroke

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirofiban (Primary)
  • Indications Ischaemic stroke
  • Focus Therapeutic Use
  • Acronyms iTREMT

Most Recent Events

  • 16 Sep 2022 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
  • 16 Sep 2022 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
  • 16 Sep 2022 Planned initiation date changed from 1 Mar 2022 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top